Infographic from the GALAXY Study showing the impact of ctDNA status on colorectal cancer outcomes. The chart compares survival rates between Signatera-positive and Signatera-negative patients at 24 and 36 months. Key prognostic factors such as ctDNA status, genetic mutations, and lymph node involvement are illustrated, along with clinical implications for treatment decisions like chemotherapy or observation.

NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024

The GALAXY Study has provided compelling data that highlights the predictive value of circulating tumor DNA (ctDNA) status in colorectal cancer outcomes. Using Natera’s Signatera test, this study offers oncologists key insights into how ctDNA can be used to monitor disease recurrence, guide therapy decisions, and potentially redefine patient management strategies. Study Design and Participants … Continue reading NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024

OncologyTube